Loading
Life sciences · Journal article
International Journal of Drug Delivery Technology · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Autoimmune rheumatic diseases (ARDs) such as systemic lupus erythematosus and rheumatoid arthritis (RA) arise from aberrant immune responses that lead to chronic inflammation and tissue damage.Conventional treatments, including biological disease-modifying antirheumatic drugs (bDMARDs), often provide limited effectiveness, failing to achieve lasting remission and sometimes causing significant adverse effects.This review aims to explore the transformative potential of innovative cellular therapies, particularly Chimeric Antigen Receptor (CAR) T cell therapy, which was initially developed for cancer treatment but may be repurposed to target and eliminate autoreactive immune cells in ARDs, thereby restoring immune balance.We synthesize current research on various cellular therapies such as stem cell therapy (SCT), tolerogenic dendritic cells (tolDCs), and regulatory T cell (Treg) therapy, focusing on their unique mechanisms of action and therapeutic effects in the context of RA.Emerging evidence from preclinical and clinical studies will be highlighted, along with the implications of epigenetic modifications that enhance the immunoregulatory potential of these therapies.While preliminary findings show promising efficacy in the management of RA, further research is crucial to establish safety profiles, clarify mechanisms of action, and evaluate long-term outcomes associated with these advanced treatments.Ultimately, this review emphasizes the critical role of cellular therapies in addressing the unmet needs of rheumatoid arthritis patients and outlines future research directions in this rapidly evolving field.